Pilot study to assess the safety and efficacy of switching the NNRTI or PI to maraviroc in HIV-1-infected subjects with persistent viremia suppression experiencing NNRTI or PI-related dyslipidemia [ENSAYO CLiNICO PILOTO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CAMBIAR EL ITINAN O EL IP A MARAVIROC EN PACIENTES INFECTADOS POR EL VIH-1 CON CARGA VIRAL INDETECTABLE Y DISLIPEMIA ASOCIADA A LOS ANTIRETROVIRALES]
Latest Information Update: 10 Sep 2012
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals; Atazanavir; Atazanavir/ritonavir; Darunavir/ritonavir; Efavirenz; Fosamprenavir; Lopinavir/ritonavir; Nevirapine; Ritonavir; Tipranavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms MARAVI-SWITCH
- 08 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 16 Jun 2011 New trial record